Lilly Q3: Mounjaro hits $10.7bn as international sales nearly double; Foundayo misses forecasts
Lilly's third-quarter revenue rose 39% to $24.4bn. Mounjaro brought in $10.7bn worldwide, with sales outside the US up 93%, while its new obesity pill Foundayo made $184m, below analyst estimates of around $229m. Lilly says about 4 in 10 US patients starting an oral obesity medicine now choose Foundayo.
Source: CNBC (29 Oct 2026). Image: CNBC.